Company intelligence / Profile preview
Yantai Chuanghe Biotechnology
Yantai, Shandong Sheng, Chinaluye.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Yantai Chuanghe Biotechnology was established in December 2021 and focuses on the development of small molecule drugs targeting neoplasms, endocrinology/metabolic diseases, and urogenital diseases. There are no publicly disclosed clinical results or advanced-stage assets as of May 2025[1].
- Therapeutic areas
- OncologyEndocrinologyNephrology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Yantai Chuanghe Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yantai Chuanghe Biotechnology.